Lucid Diagnostics (LUCD)

Company Profile

Lucid Diagnostics, Inc. (“Lucid”) is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (“GERD”), also known as chronic heartburn, acid reflux or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma (“EAC”). References in this Form 10-K to “we,” “us” and “our” are to Lucid and, unless the context otherwise requires, its subsidiaries.

Company profile

Ticker

LUCD

Exchange

Incorporated

Location

Fiscal year end

Sector

Manufacturing > Surgical and Medical Instrument Manufacturing

Industry (SIC)

Surgical & Medical Instruments & Apparatus

Baxter International • Boston Scientific • Stryker • Becton, Dickinson And • 3M • Teleflex • Resmed • Haemonetics • Hill-Rom • Nuvasive ...

SEC CIK

0001799011

Corporate docs

Underwriting Agreements

Plans of Reorganization

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

(Lucid Diagnostics Inc. • LucidDx Labs Inc. ...

IRS number

825488042

LUCD stock data

1M 1Y 5Y

Analyst ratings and price targets

Last 3 months

Average target

$3.30

Low target

$3.10

High target

$3.50

Latest filings (excl ownership)

View all

8-K

PAVmed and Lucid Diagnostics Provide Strategic Business Update

18 Jan 23

EFFECT

Notice of effectiveness

7 Dec 22

424B5

Prospectus supplement for primary offering

6 Dec 22

8-K

Unregistered Sales of Equity Securities

2 Dec 22

CORRESP

Correspondence with SEC

Lucid Diagnostics Provides Business Update and Third Quarter 2022 Financial Results

14 Nov 22

15 Aug 22

Transcripts

LUCD

Earnings call transcript

2022 Q2

16 Aug 22

LUCD

Earnings call transcript

2022 Q1

12 May 22

LUCD

Earnings call transcript

2021 Q4

29 Mar 22

Latest ownership filings

View all

Change in insider ownership

Financial summary

Financial statements Chart LUCD financial data

Quarter (USD)	Sep 22	Jun 22	Mar 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)		26.93 mm	26.93 mm	26.93 mm	26.93 mm	26.93 mm
Cash burn (monthly)		(no burn)	4.78 mm	4.38 mm	(no burn)	(no burn)
Cash used (since last report)		n/a	20.76 mm	19.01 mm	n/a	n/a
Cash remaining		n/a	6.17 mm	7.93 mm	n/a	n/a
Runway (months of cash)		n/a	1.3	1.8	n/a	n/a

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q3 2022

LUCD institutional ownership history Ownership history

77.3% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	22	31	-29.0%
Opened positions	3	11	-72.7%
Closed positions	12	13	-7.7%
Increased positions	6	5	+20.0%
Reduced positions	8	11	-27.3%

13F shares	Current	Prev Q	Change
Total value	266.11 mm	266.67 mm	-0.2%
Total shares	30.22 mm	30.38 mm	-0.5%
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
PAVM PAVmed	27.93 mm	$261.12 mm	0.0%
Luminus Management	846.66 k	$1.30 mm	-3.1%
Vanguard	319.37 k	$489.00 k	+11.3%
Nantahala Capital Management	286.43 k	$438.00 k	-7.3%
Cantor Fitzgerald, L. P.	264.65 k	$405.00 k	-20.7%
Bridgeway Capital Management	185.00 k	$283.00 k	0.0%
Kornitzer Capital Management	133.00 k	$203.00 k	0.0%
Geneos Wealth Management	40.85 k	$62.00 k	-3.8%
Geode Capital Management	39.12 k	$59.00 k	+10.3%
Verition Fund Management	36.17 k	$55.00 k	-22.6%

Largest transactions	Shares	Bought/sold	Change
Cantor Fitzgerald, L. P.	264.65 k	-69.06 k	-20.7%
MS Morgan Stanley	19.25 k	-39.09 k	-67.0%
Vanguard	319.37 k	+32.31 k	+11.3%
Luminus Management	846.66 k	-27.14 k	-3.1%
Nantahala Capital Management	286.43 k	-22.55 k	-7.3%
Ergoteles	0.00	-22.30 k	EXIT
Jane Street	15.60 k	+15.60 k	NEW
BMO Bank of Montreal	0.00	-15.52 k	EXIT
Verition Fund Management	36.17 k	-10.54 k	-22.6%
STT State Street	0.00	-10.52 k	EXIT

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

LUCD insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
31 Jan 23	Debra White	Employee stock option Common stock	Grant	Acquire A	No	No	1.31	175,000	229.25 k	175,000
31 Jan 23	Jacque J Sokolov	Employee stock option Common stock	Grant	Acquire A	No	No	1.31	175,000	229.25 k	175,000
31 Jan 23	Stanley Lapidus	Employee stock option Common stock	Grant	Acquire A	No	No	1.31	175,000	229.25 k	175,000
31 Jan 23	Cox James L	Employee stock option Common stock	Grant	Acquire A	No	No	1.31	175,000	229.25 k	175,000
31 Jan 23	Sparks Ronald M	Employee stock option Common stock	Grant	Acquire A	No	No	1.31	175,000	229.25 k	175,000